United States v. Johnson & Johnson
GPTKB entity
Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
legal case
|
| gptkbp:affiliatedWith |
gptkb:FDA
gptkb:CDC gptkb:NIDA advocacy groups state health departments |
| gptkbp:claims |
deceptive marketing practices
contributing to opioid epidemic |
| gptkbp:community_engagement |
protests
advocacy for reform |
| gptkbp:court |
gptkb:Johnson_&_Johnson
gptkb:United_States gptkb:United_States_District_Court |
| gptkbp:date |
2021
|
| gptkbp:filingDate |
2020
|
| gptkbp:future_plans |
increased regulation
public trust issues corporate accountability changes in marketing practices more lawsuits |
| https://www.w3.org/2000/01/rdf-schema#label |
United States v. Johnson & Johnson
|
| gptkbp:impact |
public health
financial loss regulatory changes state budgets stock price fluctuations reputation damage increased scrutiny |
| gptkbp:involves |
gptkb:Johnson_&_Johnson
gptkb:United_States_government |
| gptkbp:jurisdiction |
federal
|
| gptkbp:legal_principle |
strict liability
consumer protection negligence fraud product liability |
| gptkbp:legal_representation |
gptkb:Department_of_Justice
|
| gptkbp:legislation |
pharmaceutical regulations
opioid crisis legislation |
| gptkbp:media_coverage |
extensive
|
| gptkbp:notableFeature |
$230 million
|
| gptkbp:outcome |
settlement
|
| gptkbp:precedent |
pharmaceutical litigation
|
| gptkbp:public_perception |
divided
calls for reform awareness of health issues support for accountability concerns about opioids |
| gptkbp:related_to |
opioid crisis
|
| gptkbp:relatedPatent |
state lawsuits
multidistrict litigation |
| gptkbp:tactics |
denial of wrongdoing
settlement negotiations |